Kendle Experts to Present at the Drug Information Association 44th Annual Meeting

CINCINNATI, June 19 /PRNewswire-FirstCall/ -- Kendle NASDAQ: KNDL, a leading global full-service clinical research organization (CRO), today announced that several of its experts will present at the upcoming Drug Information Association (DIA) 44th Annual Meeting. The meeting is scheduled for June 22-26, 2008, at the Boston Convention and Exhibition Center in Boston, Mass. Kendle's experts will speak on key topics in the clinical development industry, including EDC, biomarkers, regulatory affairs, adaptive clinical trial design, professional development and patient access and retention.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

In addition to attending presentations by Kendle speakers, attendees at the DIA Annual Meeting may visit Kendle experts at two booths in the exhibit hall. Booth 1804 will focus on the company's global Phase I-IV service offerings and will preview its recently expanded Early Phase capabilities following the June 2 acquisition of DecisionLine Clinical Research Corporation, an early phase CRO specializing in the conduct of Phase I studies involving the measurement of pharmacodynamic effects of central nervous system (CNS) drugs. Booth 456 will focus on career opportunities at Kendle.

    Kendle speakers include:

    June 23

      EDC: Faster Horse or Model T?
      Sylva Collins, PhD, Vice President, Global Biometrics
      10:30 a.m. - 12 p.m.

    June 24

      Biomarkers and Surrogate Endpoints: Definitions, Background, and
      Validation
      Lisa Jenkins, PhD, Regulatory Group Leader
      8 - 9:30 a.m.

      General Process and Best Practices for EOP2 and Pre-NDA Meetings
      Lisa Jenkins, PhD, Regulatory Group Leader
      10 - 11:30 a.m.

      Recent Advances in Adaptive Clinical Trial Designs
      Lisa Jenkins, PhD, Regulatory Group Leader
      2 - 3:30 p.m.

    June 25

      Marketing Yourself as a Candidate in a Competitive Clinical Research Job
      Market
      Bill Neese, MBA, Director, Global Recruitment
      10:30 a.m. - 12 p.m.

    June 26

      Global Patient Recruitment and Retention: Identifying and Overcoming
      Barriers to Accelerate Patient Recruitment and Retention Worldwide
      Janet Jones, PhD, Senior Director, Strategic Patient Access
      8:30 - 10 a.m.

About Kendle

Kendle International Inc. NASDAQ: KNDL is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at www.kendle.com .

Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
William L Wherle
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=26220